Sarepta Therapeutics (SRPT) Lowers Guidance
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($3.42), $5.38 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $774.9 million versus the consensus estimate of $695.9 million.
GUIDANCE:
Sarepta Therapeutics sees FY2025 revenue of $2.3-2.6 billion, versus the consensus of $3.07 billion.
2025 Financial Guidance
| Updated Guidance | Prior Guidance | Assumptions |
| As of May 6, 2025 | As of February 26, 2025 |
|
Total net product revenues | $2,300 - $2,600M | $2,900 - $3,100M | Reflects updated ELEVIDYS outlook |
Combined non-GAAP R&D and SG&A expenses | $1,784 - $2,184M | $1,200 - $1,300M | Consistent operating expense outlook from prior guidance, now includes Arrowhead collaboration: |
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.